TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN)
will hold an Analyst and Investor Day in New York on Monday, June 8,
2015, from 9:00 a.m. to 11:00 a.m. ET. A live webcast of the event will
be available via the Investors section of Compugen’s website at www.cgen.com.
An archived replay of the webcast will be available on the website until
July 15, 2015.
Presentations will be presented by members of Compugen’s management
team. The event will also feature a presentation by Professor Drew
Pardoll, M.D., Ph.D., Professor of Oncology, and Director, Cancer
Immunology Program at Johns Hopkins School of Medicine, the Sidney
Kimmel Comprehensive Cancer Center. Prof. Pardoll is a member of
Compugen’s Scientific Advisory Board.
About Compugen
Compugen is a leading predictive drug discovery company focused on
monoclonal antibodies and therapeutic proteins to address important
unmet needs in the fields of oncology and immunology. The Company
utilizes a broad and continuously growing integrated infrastructure of
proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational biology
capabilities for the in silico (by computer) prediction and
selection of novel drug target candidates, which are then advanced in
its Pipeline Program. The discovery and development of monoclonal
antibody therapeutic candidates against selected Compugen-discovered
novel target candidates is performed by Compugen’s wholly-owned US
subsidiary located in South San Francisco. The Company's business model
includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery agreements,
in both cases providing Compugen with potential milestone payments and
royalties on product sales or other forms of revenue sharing. For
additional information, please visit Compugen's corporate website at www.cgen.com.